CDKN2A and neoplasm: The different metastatic behavior of RMSp53Neu-1 and RMSp53Neu-5 after CDKN2A silencing might refect tumor heterogeneity, and suggest the need of further studies to test the role of CDKN2A as a therapeutic target.